Agios Pharmaceuticals (AGIO) Insider Ballal Buys 14,950 Shares

Rahul Ballal recently acquired 14,950 shares of Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) on June 18, 2026. This transaction was not part of a pre-arranged trading plan. The shares were bought at an unspecified price and value.

Other Institutional Activity in Agios Pharmaceuticals

Several institutional investors have also adjusted their holdings in Agios Pharmaceuticals. BlackRock, Inc. increased its position by 519,528 shares, bringing its total to 5,754,957 shares worth approximately $194.7 million, a 9.9% increase. Farallon Capital Management LLC added 524,495 shares, ending with a total of 5,684,000 shares valued at $192.3 million, marking a 10.2% increase. State Street Corp boosted its holdings by 256,734 shares to 3,364,879 shares, valued at about $113.7 million, an 8.3% rise. On the other hand, Armistice Capital, LLC reduced its stake by 320,000 shares to 2,716,000 shares, a 10.5% decrease, while Erste Asset Management GmbH cut 100,000 shares, resulting in 2,704,900 shares.

Agios Pharmaceuticals, Inc. Stock Up 7.2%

Shares of Agios Pharmaceuticals traded near $35.47 on Wednesday. The company has a market capitalization of approximately $2.09 billion. Agios is not currently profitable, reflected in its negative forward P/E ratio of -7.44. The stock's 52-week range spans from $22.24 to $46.00, with a 50-day moving average of $29.03 and a 200-day moving average of $31.74. The company's beta is 0.587, indicating lower volatility compared to the market. Agios maintains a robust financial position, with a current ratio of 14.19 and a quick ratio of 12.80.

Insider Buying and Selling at Agios Pharmaceuticals, Inc.

On June 18, 2026, several insiders acquired shares of Agios Pharmaceuticals. Rahul Ballal, Jacqualyn Fouse, David Scadden, Jay Backstrom, and Cynthia Smith each purchased 14,950 shares, except for Smith, who bought 2,816 shares. These purchases were not executed under Rule 10b5-1 plans.

Analysts Set New Price Targets

Analysts have maintained their ratings on Agios Pharmaceuticals with various price targets. On June 11, 2026, JP Morgan maintained a 'hold' rating with a $31.00 target. B of A Securities, on May 29, 2026, kept a 'buy' rating, setting a $40.00 target. The consensus among analysts is a 'buy' rating, with a mean target price of $40.75 based on eight opinions.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts. It focuses on discovering and developing medicines in cellular metabolism. The company's key product, PYRUKYND, is used to treat hemolytic anemias and is undergoing trials for sickle cell disease. Agios also develops treatments for other conditions like myelodysplastic syndrome and phenylketonuria. Led by CEO Brian M. Goff, the company employs 539 people.

Bottom Line

Insider transactions like Rahul Ballal's purchase of Agios Pharmaceuticals shares can often signal confidence in the company's future. Shares traded near $35.47, with a market cap of around $2.09 billion. Analysts maintain a favorable outlook, with a consensus 'buy' recommendation and a target mean price of $40.75. Investors should note that insider transactions are disclosed after the fact and may not indicate current positions.